Results 21 to 30 of about 27,891 (313)

Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes

Biomedicines, 2021
Background: An unexpected increase in the rate of severe diabetic retinopathy was observed in the Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN)-6 clinical trial.
Rafael Simó, Patricia Bogdanov, Hugo Ramos, Jordi Huerta, Olga Simó-Servat, Cristina Hernández   +5 more
doaj   +1 more source

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

New England Journal of Medicine, 2021
BACKGROUND Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes.
J. Frias, M. Davies, J. Rosenstock, Federico C. Pérez Manghi, L. Fernández Landó, B. Bergman, Bing Liu, Xuewei Cui, K. Brown   +8 more
semanticscholar   +1 more source

Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. [PDF]

, 2018
Altres ajuts: C.M. is supported by the Deutsche Forschungsgemeinschaft (DFG; SFB 894, TRR-219, and Ma 2528/7-1), the German Federal Ministry of Education and Science (BMBF; 01EO1504) and the Corona foundation. J.B.
12, 19, 29, 31 32, 33, 6, Alessandra Dei Cas18, Alexander R. Lyon24, and Stephane Heymans, Antoni Bayes-Genis11, Arantxa Gonza´lez20, Bart Staels30, Christoph Maack1, ChristophWanner35, Dimitrios Farmakis36, Dirk Brutsaert13, Francesco Cosentino16, Frank R. Heinzel4, Frank Ruschitzka37, Gerasimos Filippatos36, Gilles De Keulenaer17, Giuseppe Rosano28, Graham Rena26, Guido Iaccarino, Heiko Bugger14, Heinrich Taegtmeyer9, Ida Gjervold Lunde23, Jean-Sebastien Hulot5, Johann Bauersachs10, Johannes Backs3, Kieran Clarke15, LindaW. van Laake34, Martin Huelsmann21, Michael Lehrke2, Niels P. Riksen27, Nikolaus Marx2, Patrick Rossignol8, Petar Seferovic38, Piero Pollesello25, Rudolf A. de Boer39, Walter J. Paulus7   +40 more
core   +20 more sources

Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis

Frontiers in Pharmacology, 2021
Background: Cardio-renal profiles are available from cardiovascular outcome trials of glucagon-like peptide-1 receptor agonists (GLP-1 RAs).Methods: A comprehensive systematic review of Embase, Medline, Web of Knowledge, and CENTRAL databases was ...
Chuanjun Zhuo, Chuanjun Zhuo, Chuanjun Zhuo, Chuanjun Zhuo, Chongguang Lin, Chunhua Zhou, Xiangyang Gao, Hailin Shao, Tao Fang, Hongjun Tian, Li Ding, Ming Liu   +11 more
doaj   +1 more source

Clinical Pharmacokinetics of Semaglutide: A Systematic Review

Drug Design, Development and Therapy
Xi-Ding Yang,1,2 Yong-Yu Yang1,3 1Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, Hunan, People’s Republic of China; 2Phase I Clinical Trial Center, The Second Xiangya Hospital of Central South University ...
XiDing Yang, Yong-Yu Yang
exaly   +2 more sources

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

Cardiovascular Diabetology, 2020
Background Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2 diabetes (T2D) available in subcutaneous (s.c.) and oral formulations.
Mansoor Husain, Stephen C. Bain, Anders Gaarsdal Holst, Thomas Mark, Søren Rasmussen, Ildiko Lingvay   +5 more
doaj   +1 more source

Shared genetic contribution of type 2 diabetes and cardiovascular disease: Implications for prognosis and treatment [PDF]

, 2018
Purpose of Review: The increased cardiovascular disease (CVD) risk in subjects with type 2 diabetes (T2D) is well established. This review collates the available evidence and assesses the shared genetic background between T2D and CVD: the causal ...
Strawbridge, Rona J., van Zuydam, Natalie R.   +1 more
core   +1 more source

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review

Clinical Epidemiology, 2022
Zeyu Xie, Sensen Yang, Weishang Deng, Jinjian Li, Jisheng Chen Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Xie Z, Yang S, Deng W, Li J, Chen J
doaj  

Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial [PDF]

, 2017
Objectives: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
Bolli, Geremia B., Kothny, Wolfgang, Kozlovski, Plamen, Krum, Henry, Lewsey, James D., Lukashevich, Valentina, McMurray, John J.V., Ponikowski, Piotr   +7 more
core   +2 more sources

Some doubts about the mantra on the deleterious cardiovascular effects of sulfonylureas [PDF]

, 2017
[No abstract ...
Prudente, Sabrina, Trischitta, Vincenzo
core   +1 more source